Biopharma & Life Sciences
Armata Pharmaceuticals Executive Compensation (FY25)
ARMP · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Deborah Birx | Latest say-on-pay support = June 11, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Armata Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 28, 2026Latest filing (8-K): June 16, 2026
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
152 figures on this page: 145 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Deborah Birx: $1,584,176 → $1,249,889 (21.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Armata Pharmaceuticals' chief executive and what were they paid?
Total compensation for Deborah Birx, Chief Executive Officer, came to $1,249,889 in fiscal 2025. Birx's total moved 21.1% lower from the $1,584,176 reported for fiscal 2024.
What was Armata Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 99.9% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Brian Varnum Former Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Mina Pastagia Chief Medical Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Erin Butler Former Vice President, Finance Administration | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Steve Martin Former Chief Financial Officer (4) Departed during or after this year | ◇ | — | — | — | — | — | — | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Deborah Birx Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Brian Varnum Former Chief Executive Officer Departed during or after this year | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Mina Pastagia Former Chief Medical Officer | ◇ | — | — | — | — | — | ◇ | ◇ |
Erin Butler Former Vice President, Finance Administration Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Richard Rychlik Former Vice President, Corporate Controller | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Deborah Birx Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Mina Pastagia Former Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Pierre Kyme Chief Business Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Richard Rychlik Former Vice President, Corporate Controller Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
David House Senior Vice President, Finance and Principal Financial Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Deborah Birx Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Pierre Kyme Chief Business Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
David House Senior Vice President, Finance and Principal Financial Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Deborah Birx | Option | ◇ | — | ◇ | 2/5/2035 |
| Option | ◇ | — | ◇ | 3/14/2034 | |
| Option | ◇ | — | ◇ | 12/21/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Pierre Kyme | Option | ◇ | — | ◇ | 2/5/2035 |
| Option | ◇ | — | ◇ | 3/14/2034 | |
| Option | ◇ | — | ◇ | 4/13/2032 | |
| RSU | ◇ | ◇ | — | — | |
| David House | Option | ◇ | — | ◇ | 10/2/2034 |
| Option | ◇ | — | ◇ | 2/5/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Robin C. Kramer Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Joseph Patti | ◇ | — | ◇ | — | — | — | ◇ |
Sarah J. Schlesinger | ◇ | — | ◇ | — | — | — | ◇ |
Todd Peterson | ◇ | — | ◇ | — | — | — | ◇ |
Odysseas Kostas | ◇ | — | ◇ | — | — | — | ◇ |
Jules Haimovitz | ◇ | — | ◇ | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 12, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | September 14, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | November 16, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 7, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | December 8, 2020 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Deborah Birx (Chief Executive Officer), FY2025 total compensation $1,249,889 (base salary $562,380) [exec_comp, SEC accession 0001104659-26-049437, filed 2026-04-27]What this page does not include
Everything above is a fact Armata Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
152 figures on this page: 145 cited to the filing that reported them, 7 calculated from figures it prints.
145 cited to the filing
7 calculated from the filing
Documents cited
- 0001104659-26-074618Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-26-049437
- 0001104659-25-059346Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-25-040273
- 0001104659-24-071752Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-24-054149
- 0001104659-23-102132Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001558370-23-004014
- 0001104659-22-120162Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-21-080368Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0001104659-20-133433Item 5.07 Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Armata Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ARMP (accessed 2026).
Short form: data: Velarion
The Armata Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Armata Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}